TY - JOUR
T1 - Pegaptanib sodium for the treatment of age-related macular degeneration
AU - Apte, Rajendra S.
N1 - Funding Information:
Editorial support, including contributing to the development of the manuscript and styling the paper for journal submission, was provided by Dr Linda Whetter of Zola Associates and was funded by (OSI) Eyetech and Pfizer, Inc.
PY - 2008/2
Y1 - 2008/2
N2 - Background: Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeability. Objective: To briefly present the pharmacology, clinical efficacy and safety, and role of pegaptanib in treating ocular neovascular diseases. Methods: A systematic literature review and synopsis. Results/conclusion: After more than 10 years in development, clinical trials have shown pegaptanib efficacy in treating choroidal neovascularization of age-related macular degeneration. Its excellent ocular and systemic safety profiles have been confirmed in up to 3 years of experience. Early phase, well-controlled studies also suggest therapeutic benefit in diabetic retinopathy and retinal vein occlusion.
AB - Background: Pegaptanib sodium, the first aptamer therapeutic approved for use and the first antiangiogenic agent used to treat ocular neovascular disease, acts by inhibiting the 165 isoform of vascular endothelial growth factor believed primarily responsible for pathologic ocular neovascularization and vascular permeability. Objective: To briefly present the pharmacology, clinical efficacy and safety, and role of pegaptanib in treating ocular neovascular diseases. Methods: A systematic literature review and synopsis. Results/conclusion: After more than 10 years in development, clinical trials have shown pegaptanib efficacy in treating choroidal neovascularization of age-related macular degeneration. Its excellent ocular and systemic safety profiles have been confirmed in up to 3 years of experience. Early phase, well-controlled studies also suggest therapeutic benefit in diabetic retinopathy and retinal vein occlusion.
KW - Age-related macular degeneration
KW - Aptamer
KW - Choroidal neovascularization
KW - Pegaptanib
KW - Vascular endothdial growth factor
UR - http://www.scopus.com/inward/record.url?scp=39049142223&partnerID=8YFLogxK
U2 - 10.1517/14656566.9.3.499
DO - 10.1517/14656566.9.3.499
M3 - Review article
C2 - 18220500
AN - SCOPUS:39049142223
SN - 1465-6566
VL - 9
SP - 499
EP - 508
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 3
ER -